Filtered Listing Testing
Download the fall 2014 issue of our Alzheimer’s disease newsletter to learn about a drug compound that reversed Alzheimer’s effects on memory in mice, new grants that will fund Alzheimer’s research, and much more.
After centuries of health and economic disparity, women have emerged as a strong force in the U.S. and worldwide. Yet a crisis of inequality looms ahead.
Is there anyone who hasn’t “put a face” on Alzheimer’s? We only have to picture our grandparents, parents, spouses, friends, neighbors, or even siblings who have struggled with the disease. Yet there’s another face hidden in the picture.
BrightFocus grantee Huaxi Xu, PhD and colleagues at the Sanford-Burnham Medical Research Institute in La Jolla, CA, have published a paper that sheds light on the origins and connections between the characteristic amyloid plaques found in the brains of individuals with Alzheimer’s disease and the predisposition of individuals with Down syndrome to develop the same plaques, and exhibit Alzheimer’s-type dementia, as they age.
This week, at a meeting in Bethesda, MD, a group of experts pondered what works to measure "clinical meaningfulness" in drug development for early Alzheimer's disease.
A leading government science officer addressed BrightFocus grantees attending our annual breakfast sponsored during the Society for Neuroscience (SfN) meeting, which was held in Washington, DC, this week.
More than 250 science journalists covered the Society for Neuroscience meeting in Washington, DC, this week. Two close colleagues of BrightFocus took part in press conferences to explain new directions in Alzheimer’s research.